The UK’s ability to secure a resilient supply of medical radionuclides is increasingly recognized as a matter of public health, industrial strategy, and national resilience. Radionuclides underpin a wide range of diagnostic imaging and therapeutic treatments, yet their production and supply chains are complex, highly regulated, and vulnerable to disruption.
Medical radionuclides and the UK Regulatory Framework
What the latest Regulatory Study means for government and innovators, and the challenge of strengthening the UK’s health system and industrial capability.